secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ginkgo Bioworks Holdings, Inc. (DNA)
CIK:        0001830214
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0000950170-23-040716
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ginkgo Q2 revenue $81M (-44% YoY); Cell Engineering services up 72%; guides FY23 rev $245-260M
--------------------------------------------------------------------------------

- Q2 total revenue $81M, down 44% YoY as Biosecurity K-12 testing wound down.
- Cell Engineering services revenue $44M, up 72% YoY; total Cell Engineering $45M.
- Biosecurity revenue $35M (49% gross margin); expanding internationally.
- Adjusted EBITDA loss $(75)M; operating loss $(184)M including $62M stock comp.
- FY23 guidance: total rev $245-260M, Cell Eng rev revised to $145-160M, Bio at least $100M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1830214/000095017023040716/0000950170-23-040716-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1830214/000095017023040716/dna-20230809.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-040716

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer